Effect of the degree of resection on the first and second relapse-free period of patients with primary glioblastoma in the era of modern chemoradiotherapy

первичная глиобластома, ген MGMT , степень резекции опухоли

1. Nabors L. B. Central Nervous System Cancers. Version 3.2020. NCCN Clinical Practice Guidelines in Oncology / L. B. Nabor, J. Portnow, M. A hluwalia, J. Baehring, H. Brem, S. Brem, N. Butowski, J. L . Campian, S. W. Clark, A. J. Fabiano, P. Forsyth, J. Hattangadi-Gluth, M. Holdhoff, C. Horbinski, L. Junck, T. Kaley, P. Kumthekar, J. S. L oeffler, M. M . M rugala, S. Nagpal, M. Pandey, I. Parney, K. Peters, V. K. Puduvalli, I. R obins, J. R ockchill, C. R usthoven, N. Shonka, D. S. Shrieve, L. J. Swinnen, S. Weiss, P. Y . Wen, N. E. Willmarth, M. A . Bergman, S. D. Darlow // J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537–1570. DOI: 10.6004/jnccn.2020.0052.

2. Клинические рекомендации. Первичные опухоли центральной нервной системы. Разработчики: Ассоциация онкологов России, Ассоциация нейрохирургов России, Российское общество клинической онкологии. Одобрены научным советом Министерства Здравоохранения РФ / ред.совет.: Коновалов Н. А. и др. 2020.

3. Glas M. L ong-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide / M. G las, C. Happold, J. R ieger, D. Wiewrodt, O. Bähr, J. P. Steinbach, W. Wick, R. D. Kortmann, G. R eifenberger, M. Weller, U. J. Herrlinger // Clin Oncol.– 2009.– 10;27(8).– 1257–61. DOI: 10.1200/JCO.2008.19.2195.

4. Zhang C. Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor / C. Zhang, Y. Y ao, Y. Wang, Z. Chen, J. Wu, Y. M ao, L. Zhou // Int J Neurosci.– 2010.– 120(12).– 787–91. DOI: 10.3109/00207454.2010.520377.

5. Gessler F. Surgery for glioblastoma in light of molecular markers: impact of resection and MGM T promoter methylation in newly diagnosed IDH‑1 wild-type glioblastomas / F. G essler, J. D. Bernstock, S. L escher, P. Baumgarten, P. N. Harter, M. M ittelbronn, T. Wu, V. Seifert, C. Senft // Neurosurgery.– 2019.– 1;84(1).– 190–197. DOI: 10.1093/neuros/nyy049.

6. Amelot A. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients / A. A melot, P. De Cremoux, V. Quillien, M. Polivka, H. A dle-Biassette, J. L ehmann-Che, L. Françoise, A. F. Carpentier, B. G eorge, E. M andonnet, S. Froelich // PLoS One.– 2015.– 9;10(7): e0130596. DOI: 10.1371/journal.pone.0130596.

7. Ringel F. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection / F. R ingel, H. Pape, M. Sabel, D. Krex, H. C. Bock, M. M isch, A. WeyerBrock, T. Westermaier, C. Senft, P. Schucht, B. M eyer, M. Simon // Neuro-Oncology.– 2015.– 0.– 1–9. DOI: 10.1093/neuonc/nov145.

8. Byun J. Comparison of survival outcomes between partial resection and biopsy for primary glioblastoma: a propensity score-matched study / J. Byun, Y. H. Kim, S. J. Nam, J. E. Park, Y. H. Cho, H. S. Kim // World Neurosurg.– 2019.– 121: e858–66. DOI: 10.1016/j.wneu.2018.0 9.237.

9. Kim Y. J. O ptimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era / Y. J. Kim, D. J. L ee, C. K. Park, I. A . Kim // Neurosurg Rev.– 2019.– 42(4).– 937–950. DOI: 10.1007/s10143‑018‑01071‑3.

10. Мацко М. В. Морфологические и молекулярно-генетические особенности первичных глиобластом у пациентов с необычно высокой продолжительностью жизни / Мацко М. В., Волков Н.М., Улитин А.Ю., Моисеенко В.М., Имянитов Е. Н., Иевлева А.Г. // Сибирский онкологический журнал.– 2019.– 18(3).– 34–44. DOI: 10.21294/1814‑4861‑2019‑18‑3‑34‑44.

11. Yu W. O6-Methylguanine-DNA Methyltransferase (MGM T): Challenges and New Opportunities in Glioma Chemotherapy / W. Y u, L. Zhang, Q. Wei, A. Shao // Front Oncol.– 2019.– 9.– 1547. DOI: 10.3389/fonc.2019.01547.

12. Schaff L. R . Characterization of MGM T and EGFR protein expression in glioblastoma and association with survival / L. R . Schaff, D. Y an, S. Thyparambil, Y. Tian, F. Cecchi, M. R osenblum, A. S. R einer, K. S. Panageas, T. Hembrough, A. L . L in // J Neurooncol.– 2020–146(1).– 163–170. DOI:10.1007/s11060–019–03358-x.

13. Lukas R. V . Newly Diagnosed Glioblastoma: A Review on Clinical Management/ R. V . L ukas, D. A . Wainwright, E. L adomersky, S. Sachdev, A. M . Sonabend, R. Stupp // Oncology (Williston Park).– 2019. – March.– 13; 33(3).– 91–100.

14. Hegi M. E. M gmt gene silencing and benefit from temozolomide in glioblastoma/ M. E. Hegi, A. C. Diserens, T. G orlia, M. F. Hamou, N. de Tribolet, M. Weller, J. M . Kros, J. A . Hainfellner, W. M ason, L. M ariani, J. E. Bromberg, P. Hau, R. O . M irimanoff, J. G . Cairncross, R. C. Janzer, R. N. Stupp // Engl. J. M ed.– 2005.– 352.– 997‑1003. DOI:10.1056/NEJMoa043331.

15. Matsko M. V . Predictive role of O6-methylguanine DNA methyltransferase status for the treatment of brain tumors / M. V . M atsko, E. N. Imaynitov // Epigenetics Territory and Cancer.– 2015.– 251–279. DOI:10.1007/978‑94‑017‑9639‑2_9.

16. Quick J. Benefit of tumor resection for recurrent glioblastoma / J. Quick, F. G essler, Dutzmann, E. Hattingen, P. N. Harter, L. M . Weise, K. Franz, V. Seifer, C. Senft // J Neurooncol.– 2014. – Apr; 117(2).– 365–72. DOI: 10.1007/s11060‑014‑1397‑2.

17. Lu V . M . The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis / V. M . L u, T. R . Jue, K. L . M cDonald, R. A . R ovin // World Neurosurg.– 2018 Jul.– 115.– 453–459.e3. DOI: 10.1016/j.wneu.2018.04.016.

18. Louis D.N. WHO Classification of Tumours of the Central Nervous System / D. N. L ouis, H. O hgaki, O. D. Wiestler, W. K. Cavenee, eds. – Lyon. Revised 4th edition. International Agency for Research on Cancer. 2016.

19. Mitiushkina N. V . Detection of EGFR mutations and EML 4-AL K rearrangements in lung adenocarcinomas using archived cytological slides / N. M . M itiushkina, A. G . Iyevleva, A. N. Poltoratskiy, A. O . Ivantsov, A. V . Togo, I. S. Polyakov, S. V . O rlov, D. E. M atsko, V. I. Novik, E. N. Imyanitov // Cancer Cytopathol.– 2013.– 121.– 370–376. DOI: 10.1002/cncy.21281.

20. Stupp R. R adiotherapy plus concomitant and adjuvant temozolomide for glioblastoma / R. Stupp, W. P. M ason, M.J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A . Brandes, C. M arosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. L udwin, T. G orlia, A. A llgeier, D. L acombe, J. G . Cairncross, E. Eisenhauer, R. O . M irimanoff // N. Engl. J. M ed.– 2005.– 352.– 987–996. DOI: 10.1056/NEJMoa043330.

21. Kreth F. W. G ross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy / F. W. Kreth, N. Thon, M. Simon, M. Westphal, G. Schackert, G. Nikkhah, B. Hentschel, G. R eifenberger, T. Pietsch, M. Weller, J. C. Tonn // Annals of Oncology.– 2013.– 24(12).– 3117–312. DOI: 10.1093/annonc/mdt388.

22. Marchi F. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGM T Deregulation / F. M archi, N. Sahnane, R. Cerutti, D. Cipriani, J. Barizzi, F. M . Stefanini, S. Epistolio, M. Cerati, S. Balbi, L. M azzucchelli, F. Sessa, G. A . Pesce, M. R einert, M. Frattini // Frontiers in Oncology.– 2020.– 24;9:1569. DOI: 10.3389/fonc.2019.01569.

23. Paldor I. Frontal glioblastoma multiforme may be biologically distinct from non-frontal and multilobar tumors / I. Paldor, F. C. Pearce, K. J. Drummond, A. J. Kaye // Clin Neurosci.– 2016.– 34.– 128–132. DOI: 10.1016/j.jocn.2016.05.017.

24. Lee J. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival / J. L ee, S. S. A hn, J. H. Chang, C. Suh // Yonsei Med J.– 2018.– 59(2).– 194–201. DOI:10.3349/ymj.2018.59.2.194.

25. Azoulay M. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution / M. A zoulay, F. Santos, G. Shenouda, K. Petrecca, K. O weida, M. C. G uiot, S. O wen, Panet-Raymond, L. Souhami, B. S. A bdulkarim // J Neurooncol.– 2017. –132(3).– 419–426. DOI: 10.1007/s11060‑017‑2383‑2.

26. Franceschi E. Temozolomide rechallenge in recurrent glioblastoma: when is it useful? / E. Franceschi, G. L amberti, M. V isani, A. Paccapelo, A. M ura, G. Tallini, A. Pession, D. D. Biase, S. M inichillo, A. Tosoni, M. D. Battista, A. Cubeddu, S. Bartolini, A. A . Brandes // Future Oncol.– 2018.– 14(11).– 1063–1069. DOI: 10.2217/fon‑2017–0681.

27. Sadones J. MGM T promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma / J. Sadones, A. M ichotte, C. Chaskis, R. Sciot, J. M enten, E. J. Joossens, T. Strauven, L.A. D’Hondt, D. Sartenaer, S. F. Califice, K. Bierau, C. Svensson, J. De Grève, B. Neyns // Eur. J. Cancer.– 2009.– 45(1).– 146–153. DOI: 10.1016/j.ejca.2008.09.002.